Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion ...

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Morningstar brands and products Company Portfolio ...

Daiichi Sankyo has a leading ADC platform, a cutting-edge modality for cancer treatments that improves upon the safety and efficacy of existing chemotherapy treatments. Enhertu has demonstrated ...

Recommendation based on DESTINY-Lung02 trial results, which showed Daiichi Sankyo and AstraZeneca’s ENHERTU achieved strong and durable tumor responses in previously treated HER2 mutant disease ...

Daiichi Sankyo and AstraZeneca's ENHERTU has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for the treatment of a specific type of metastatic ...

Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results Eleventh Breakthrough Therapy ...

That has now been reversed, according to Daiichi Sankyo, which in the interim lost a patent infringement suit claiming that AstraZeneca-partnered Enhertu (trastuzumab deruxtecan) infringed the ...